379.00
+1.7(+0.45%)
Currency In INR
| Previous Close | 377.3 |
| Open | 375.4 |
| Day High | 383.85 |
| Day Low | 372.95 |
| 52-Week High | 424.95 |
| 52-Week Low | 291 |
| Volume | 3.55M |
| Average Volume | 3.43M |
| Market Cap | 506.71B |
| PE | 95.23 |
| EPS | 3.98 |
| Moving Average 50 Days | 392.95 |
| Moving Average 200 Days | 363.66 |
| Change | 1.7 |
If you invested ₹1000 in Biocon Limited (BIOCON.NS) 10 years ago, it would be worth ₹4,504.93 as of January 14, 2026 at a share price of ₹379. Whereas If you bought ₹1000 worth of Biocon Limited (BIOCON.NS) shares 5 years ago, it would be worth ₹819.69 as of January 14, 2026 at a share price of ₹379.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 12:26 PM GMT
•New oncology assets to include proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®) •Company to outline integration as a wholly owned subsidiary into Bio
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
GlobeNewswire Inc.
Jul 15, 2025 7:25 PM GMT
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today annou